Viking Therapeutics VKTX
NASDAQ VKTX
$28.44 -0.22 (-0.77%)
At close: Nov 11, 2026 · 4:00 PM EST

Viking Therapeutics (VKTX) Research & Development (2014 - 2026)

Updated

Viking Therapeutics (VKTX) recorded Research & Development of $166.8 million in Q3 2026, up 85.4% from $89.95 million a year earlier and up 44.1% from the prior quarter.

Analysis

Viking Therapeutics (VKTX) Research & Development (2014 - 2026) Analysis & Trends

On a TTM basis, Viking Therapeutics' Research & Development came in at $586.17 million as of Sep 30, 2026, up 163.5% year-over-year; for FY2025, it was $344.96 million, up 239.4% from FY2024.

  • Annual Research & Development has increased for ten straight years, with a five-year compound annual growth rate of 61.0% (FY2020 to FY2025).
  • Across earlier years, Research & Development came in at $101.64 million in FY2024 (+59.3%), $63.81 million in FY2023 (+17.6%), $54.23 million in FY2022 (+20.6%) and $44.98 million in FY2021 (+40.9%).
  • The Q3 2026 figure is the highest quarterly Research & Development in data going back to Q1 2014.
  • On a year-over-year basis, Research & Development has increased for 14 consecutive quarters, with growth averaging 175.8% over the last eight quarters.
  • Peak year-over-year performance for Research & Development in the last five years was growth of 395.2% in Q4 2025, against a decline of 12.3% in Q1 2023 at the low end.
  • Per Business Quant, the preceding three quarters came in at $115.75 million (Q2 2026), $150.15 million (Q1 2026) and $153.46 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 4.25 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 4.65 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.57 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.54 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 3.89 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 2.11 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 1.61 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 3.02 Bn
10 Viking Therapeutics 3.65 Bn 884.58 Mn - 166.80 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 166.80 Mn
Jun 30, 2026 115.75 Mn
Mar 31, 2026 150.15 Mn
Dec 31, 2025 153.46 Mn
Sep 30, 2025 89.95 Mn
Jun 30, 2025 60.15 Mn
Mar 31, 2025 41.39 Mn
Dec 31, 2024 30.99 Mn
Sep 30, 2024 22.79 Mn
Jun 30, 2024 23.77 Mn
Mar 31, 2024 24.10 Mn
Dec 31, 2023 20.50 Mn
Sep 30, 2023 18.38 Mn
Jun 30, 2023 13.92 Mn
Mar 31, 2023 11.01 Mn
Dec 31, 2022 16.18 Mn
Sep 30, 2022 11.96 Mn
Jun 30, 2022 13.54 Mn
Mar 31, 2022 12.56 Mn
Dec 31, 2021 9.85 Mn
API Access

Viking Therapeutics Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=VKTX&period=max&api_key=YOUR_API_KEY